Objetctives. Primary central nervous system lymphoma (PCNSL) is a rare patology and is most often seen in immunodeficient patients. This article presents our casuistic of PCNSL in immunocompetent patients and make a literature review on this issue with focus on recent advances, investigations, and controversies in diagnosis and management of this patology.
Introduction
Primary central nervous system lymphoma (PCNSL) is rare and is most oftn seen in inmunodeficient patients. These tumors constitute 0.3-1.5% of all intracranial neoplasms in patients without AIDS 26 .
The majority are the Non-Hodgkin type and are high grade 19 . They are mainly B-cell lymphomas (96.4%) were T-cell type tumors 3, 21 . Nevertheless, clinical manifestations, management, and outcome of T-cell lymphoma (3.6% of all PCNSL) are very similar to those of B-cell lymphoma 28 . Primary Burkitt lymphoma of the CNS in inmunocompetent individuals has rarely been reported 19 . The CNS lymphomas are associated with other CNS tumours as pontocerebellar angle schwannoma 17 , anaplastic oligodendrogliomas 13 .
Matherial and methods
Nine patients operated in the last years in our clinics are analysed in relation to sex, age, time of symptoms, procedures and adjuvant treatment. The neuroradiological exams, history of the disease, prescriptions, evolution, surgery report and anatomo-pathological exams are reviewed and analysed. Posteriorly the results are compared with those in the preview literature.
Results
The middle age of our series varied from 44-68 years, with a mean age of 60,6 years. The female sex was predominant with 62,5% of our patients. The time of symptoms at presentation ranged from 1-6 months with a mean of 3,2 months. The most common symptoms found at presentation were hemiparesis (75%), headache (37,5%), seizures (25%) and ataxia (25%). Other clinical finds were afasia, Parinaud syndrome, nistagmus, dismetry and intracranial hypertension. Histollogically there were predominance of Difuse B Type, followed by Big B Cells Type. In relation to anatomy, the tumors affected indistinctly the parietal, frontal and temporal lobe with the same frequency (25%). Other affected localizations were Sylvian fissure, paraventricular and posterior thalamic region.
Five patients were diagnosed with stereotaxic biopsy (56%), three patients were directly operated (37,5%) and one patient was treated with both procedures (12,5%). Five patients were submited to radiotherapy in the postoperatory (56%) and, one of these received also chemotherapy with BCNU + Procarbazina + Vincristina. We had a patient that did not accepted surgery or radiotherapy and was treated with pulsotherapy with solumedrol.
In table 1 we present the resume of data of our patients:
Discussion

Epidemiology
Although primary central nervous system lymphomas (PCNSL) represent only 1% of all non-Hodgkin's lymphomas (NHLs) 1 in recent years there has been a dramatic increase in the frequency of PCNSL in the immunocompromised and immunocompetent patient 21 . In the past 10 years the incidence has tripled in patients without AIDS 26 . Most patients presenting PCNSL are in the end of the fifth decade and the begining of the sixth 3, 5, 18, 23 . Our results were similiar, with mean age of 60,6 years. In our series 67,5% of the patients with PCNSL were female, concording with the previous literature 18 . Literature relates that about 75% of PCNSL patients have unifocal disease with a supratentorial location in 87% 3 . In our series all the patients had focal disease and all the tumors were supratentorial.
Signs and symptoms
The time from first symptoms to the diagnosis ranged from a few days to 5 months. In our series, most of the patients had between 1 and 2 months of symptoms at the time of diagnosis. This is important because the good results with combined surgery and radiotherapy treatment demand early stage of the disease.
Headache and vomiting due to IICP (increased intracranial pressure) and corresponding neurofunctional disorders due to various location of the tumors are the main clinical manifestation. In the majority of patients, the leading symptoms are: headaches, motor weakness, aphasia and memory disturbance 31 . In our study, we saw that tumours in parietal region usually affect the motor pathways leading to contralateral motor deficits in most of the patients. Seizures were also a frequent symptom in our series, although not related in previous reports.
Altough literature reports the frontal lobe as the most common site of involvement 5 , we also saw a high prevalence of tumours in temporal and parietal lobe. Tumor location in basal ganglia, corpus callosum, or fornix, infiltration of periventricular ependyma or a mirror pattern are strongly suggestive of a lesion of lymphomatous origin 3 .
Some studies indicate that nodular intracerebral lesions can reveal asymptomatic systemic lymphoma. When brain lymphoma is suspected or diagnosed, systemic workup including clinical, biological and radiological examinations is mandatory before assessing the primary or secondary nature of the disease. Node areas, skin, testis, Waldeyer's ring and adjacent structures are of special interest and should be carefully explored 10 .
Although metastasis of PCNSL are not reported in the previous literature, in our series 25% of patients with primary brain linfomas showed dissemination to lungs, showing that these lesions are not only locally agressive but can also show distant malignancy. In our opinion, all patients diagnosticated with PCNSL must be submitted to complete clinical and imagenological investigation, in order to discard the possibility of further lesions. 
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Diagnosis
Image Diagnostic
Typical neuroradiological patterns of PCNSL are 15 : -iso-or hyper-density (85,5%) on unenhanced CT scan ( Figure 1 ) with marked contrast enhancement (87,7%).
-infiltration/contact of leptomeningeal and/or ependymal spaces (97,3%) -hyperintensity on T2 with moderate oedema (80,3%) Peripheral edema may be seen in MRI (Figure 2 ). Images shows low-real signals in T1 phase, but enhanced signals in T2 phase (Figure 3 ) 31 .
Scintigraphy
The differential diagnosis of PCNSL must be made with an abscess because computed tomography (CT) and magnetic resonance imaging (MRI) exams of both entilies can have the same ring-like contrast enhancement.
In this purpose, leucocyte scintigraphy is a valuable aid allowing the differentiation between an abscess and a neoplasic lesion. The 99mTc-HMPAO leucocyte scintigraphy is positive in all abscess cases 27 .
SPECT
Some authors suggest that 123I-IMP SPECT can help to differentiate malignant lymphoma from benign lesions and other malignant brain tumors. In the case of B-cell malignant lymphoma the 123I-IMP SPECT shows increased uptake on both early and delayed images diffuse large 30 .
Stereotactic biopsy
Stereotactic brain biopsy was used to establish diagnoses of conditions in patients with brain tumors. In a series of 273 computer-assisted stereotactic brain biopsy procedures 22 , glial tumors accounted for the majority (44.4%) of biopsied lesions; metastases (12.9%) and lymphoma (11.6%) were also relatively common Due to the high probability of develop intracranial bleeding after this procedure, all patients must be treated with a coagulopathy protocol that included preoperative and postoperative administration of coagulation factors 14 . The stereotactic biopsy was used by us to confirm the diagnosis in those patients who were not in conditions to be submited to surgery. All these patients, after confirmed the suspect of PCNSL were sent to radiotherapy.
In only one patient stereotactic biopsy was followed by surgery and posterior radiotherapy. In this patient the diagnosis suspect was other and, when the histopathological exam showed a PCNSL, it was decided that the patient would be submited to complete resection followed by radiotherapy.
Histopathology
Histopathological work-up includes conventional and immunohistochemical stains perfomed on formalin fixed and paraffin embedded bioptical specimen 15 .The high percentage of accurate histopathological diagnosis in our study was based on:
-great mean sample volume per biopsy site -great number of biopsies in patients suspected to have cerebral lymphomas -MR-guided stereotactic procedures if the lesion was not clearly identifiable on CT scan.
Histologically the tumor mass is grayish in color often with a blussed borders (those located in brain surface often have rough borders) to the naked eye. Under microscope tumor cell may be seen around blood vessels with decreased cytosol (figure 4), pathologic rayokinesis and sometimes focal hemorrhage necrosis 31 The predominant histologic types of primary intracranial non-Hodgkin's lymphoma are diffuse large cell type (38%), large cell immunoblastic type (21%), and diffuse mixed small and large cell type (21%) 24 . The histiocitic type of lymphoma is very rare. Nevertheless it can be easily due to its characteristic immunophenotype featuree: positive for CD68 and lysozyme; focally positive for S-100 protein, CD45RB, and CD4; and negative for CD3, CD20, CD21/CD35, CD1a, CD30, ALK1, myeloperoxidase, glial fibrillary acidic protein, and cytokeratin 11 .
Treatment
Surgery
The majority of articles in current literature regards surgery as having little role (if any) in the treatment of PCNSL and that its utility is limited to obtaining adequate tissue for diagnosis. Nevertheless, there are some case reports of five years disease free after total surgical resection of PCNLS 26, 31 . We recommend surgery as gold standart therapy for the early excision combined with postoperatory irradiation, once it's curative if the diagnosis is precoce and it's more tolerable than chemotherapy.
Radiotherapy
Historically, radiotherapy has been the standard treatment modality for this disease and median survival was in the 15-month range 25 . The radiation therapy has been proven to prolong survival but, its use is complicated by delayed neurological toxicity, particularly among the elderly 20 . Although a high radiation dose was not associated with better prognosis 16 , better rates of complete radiographic response is observed following moderate doses of cranial irradiation (about 40 Gy followed by a 20 Gy boost to the tumor plus 2-cm margin). Although complete responders have a statistically significant survival advantage at 4 years, when compared with partial responders and nonresponders, the majority of patients who achieved complete response were dead of disease by 4 years following treatment. Based on this analysis there is no rationale for radiation dose escalation as a therapeutic strategy to combat PCNSL 9 . In addition, stereotactic radiosurgey with conventional radiotherapy may be an effective therapeutic strategy to control malignant lymphoma 30 . In our series patients submitted to stereotactic biopsy followed by radiotherapy had poorer results than those submitted to surgical resection plus radiotherapy.
Chemotherapy
Primary CNS lymphoma (PCNSL) is distinguished from other brain tumours by its striking response to chemotherapy. Nevertheless, chemotherapy is poorly tolerated and largely palliative in old patients. It must be remembered that the majority of PCNSL patients are older than 60 years, and therefore, will certainly find some kind of collateral effect of chemotherapy 18 . Progress in understanding the physiology of the bloodbrain barrier (BBB) and the pharmacology of chemotherapeutic agents has substantially improved the treatment and prognosis of this disease 20 . Administration of high dose of methotrexate and/or cytosine arabinoside may improve survival 12 . Some authors recommend a therapeutic regime including surgery, intrathecal injection and chemotherapy, especially those drugs capable of going through the bloodbrain barrier, for example high dose methotrexate MTX 32 . MTX is the single most effective agent.
The goal of delivering an adequate dose of MTX to the brain and cerebrospinal fluid (CSF) has been achieved by a variety of strategies, including systemic high dose, intraarterial injection following pharmacological disruption of the blood-brain barrier (BBB) and intrathecal administration. Some authors showed that survival was not longer in patients receiving intrathecal chemotherapy 6, 12 . A possible complication of the systemic chemotherapy is myelosuppression, and aseptic meningitis is related as result of intraventricular chemotherapy 6 . Treatment-related toxicity was manageable, however delayed neurotoxicity is seen in disease-free survivors.
MTX-based combination chemotherapy has yielded the best results but the prognosis of patients with CNS lymphomas remains significantly worse than comparable patients with systemic non-Hodgkin's lymphoma 20 .
Multi-modality therapy
The role of multi-modality therapy combining radiation therapy with chemotherapy (systemic, intrathecal, and/or intra-arterial) in PCNSL is controversial. Some authors relate that multi-modality therapy (chemotherapy plus radiotherapy) significantly enhances survival over patients treated with single modality therapy alone 2, 12, [23] [24] [25] . The hypothesis is that chemotherapy may enhance the radiation effect on normal brain tissue as well as in the tumor 24 . Nevertheless some authors showed, in a randomized trial, that there is no evidence of a benefit from postradiotherapy chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in immunocompetent adult patients with PCNSL18. An European survey recommends the treatment of primary intracerebral lymphoma with the following sequence: stereotactic biopsy sampling, chemotherapy with a methotrexate and anthracycline-based regimen, followed by cranial irradiation 3 .
Corticosteroids
Non-AIDS primary central nervous system lymphomas may respond totally or partially to corticosteroids. These corticoid-induced remissions seems to be very specific for this disease. They have been proposed as diagnostic test. The effect of these remissions on prognosis remains unknown.
Age was the only significant factor predicting remission. Duration of the first remission is of paramount importance on survival as well as the quality of first line therapy. In these conditions the absence of precise diagnosis due to corticoid-induced remissions could be dramatically deleterious 11 . We used pulsotherapy with solumedrol in 2 patients. The first case because patient family rejected any other treatment, and the other in combination with chemo and radiotherapy. The authors regard corticoids only to these special cases and do not use it in the patients submited to the combined treatment proposed (surgery plus radiotherapy).
Prognosis
Complete response is observed in about 63% of the patients submitted to chemotherapy, but 64% of the complete responders developed recurrence 16 . Among patient -or tumor-related factors, higher age, worse performance status, presence of B symptom, multiple lesions, presence of meningeal dissemination, and elevated lactate dehydrogenase (LDH) level are associated with poorer survival, whereas no significant difference was observed in prognosis with respect to sex, T/B phenotype, or histological subclassification.
It seems that the influence of various prognostic factors is greater than the effect caused by different types of chemotherapy 16 . Other clinical, biological and radiological prognostic factors found to have a favorable impact on survival are: a) age < 60 years; b) radiation therapy but without evidence of a dose-response relationship; c) radiation therapy in addition to chemotherapy; d) the use of systemic chemotherapy consisting of anthracyclines 3 . Taxes of recurrence with surgery are directilly proportional to the delay in diagnostic and treatment. Partial surgical resection is also an unfavorable prognostic factor 4 . The prognosis of patients submitted to steretactic biopsy followed by radiotherapy are poorer than those submitted to complete resection plus radiotherapy.
Local recurrence is the most common cause of failure 24 An also common pattern of PCNSL recurrence is that of cerebrospinal fluid (CSF) dissemination manifested as lymphomatous meningitis (LM) 6 . Literature reports that mean survival time, even with the best treatments is no greater than 18 months 5 . and the 5-and 10-year survival rates are about 15% and 8%, respectively 16 .
